Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.53 |
| ▸ | FYN | P06241 | 9/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626698 | 0.82 | CYP11B2 (0.52) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL624949 | 0.76 | FYN (0.55) | FYNPIK3CAHASPIN | |
| SCHEMBL625663 | 0.75 | FYN (0.56) | FYNPIK3CAHASPIN | |
| SCHEMBL627766 | 0.72 | L3MBTL1 (0.40) | — | |
| SCHEMBL1762361 | 0.70 | CYP11B1 (1.00) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1945183 | 0.70 | FYN (0.58) | FYNPIK3CA | |
| SCHEMBL1944166 | 0.69 | FYN (0.81) | FYNPIK3CAHASPIN | |
| SCHEMBL532334 | 0.68 | PIK3CA (0.64) | FYNPIK3CA | |
| SCHEMBL1945181 | 0.67 | FYN (0.87) | FYNPIK3CA | |
| SCHEMBL624430 | 0.67 | FYN (0.72) | FYNPIK3CAHASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |